Goddard J, Castle J, Southworth E, Fletcher A, et al. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. Acta Neuropathol 2023 Apr 4. doi: 10.1007/s00401-023-02566.
PMID: 37014508